BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.78), $0.18 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $243.67 million versus the consensus estimate of $220.19 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.